采用修饰的[68Ga]Ga-HER2 Affibody首次在人体验证酶解清除策略以降低肾脏放射性
本研究合成含可裂解Met-Val-Lys(MVK)连接子的[68Ga]Ga-NOTA-MVK-ZHER2:2891,在SKOV-3肿瘤小鼠行microPET,并纳入7名健康志愿者行生物分布与剂量学及体内代谢研究,另对4例HER2阳性与2例HER2阴性患者行PET/CT。结果示MVK配体在注射后1小时肾脏摄取显著低于对照配体(SUVmean 34.3 vs 45.8,P<0.05),健康志愿者尿中检出[68Ga]Ga-NOTA-Met-OH,首次在人体证明该策略可有效降低肾脏放射性蓄积。
要点
- MVK配体在健康志愿者1小时肾脏SUVmean为34.3,低于对照配体的45.8(P<0.05)。
- MVK配体与对照配体的有效剂量分别为26.1与28.7 µSv/MBq。
- 患者PET/CT示HER2阳性病灶SUVmax范围9.4-21,HER2阴性病灶为2.7-6.2。
核心结论
- 首次在人体证明酶解清除策略可有效降低肾脏放射性蓄积,该策略有望降低肽和小蛋白类放射性示踪剂的肾脏辐射剂量,尤其在放射性核素治疗领域。
研究设计与样本
- 合成含可裂解Met-Val-Lys(MVK)连接子的NOTA-MVK-ZHER2:2891并用68Ga标记,在SKOV-3肿瘤小鼠行microPET。
- 纳入7名健康志愿者,间隔1周先后注射对照配体与MVK配体行生物分布与剂量学研究,并采集尿液和血样行体内代谢研究。
- 招募4例HER2阳性与2例HER2阴性患者,于注射后2和4小时行[68Ga]Ga-NOTA-MVK-ZHER2:2891 PET/CT显像。
主要发现
- MicroPET示[68Ga]Ga-NOTA-MVK-ZHER2:2891在各时间点肿瘤摄取与[68Ga]Ga-NOTA-ZHER2:2891相当,而注射后40分钟肾脏摄取显著降低(P<0.05)。
- 健康志愿者生物分布示注射后1小时MVK配体肾脏摄取显著低于对照配体(P<0.05),SUVmean分别为34.3与45.8,两配体在其他器官摄取差异可忽略。
- MVK配体与对照配体的有效剂量分别为26.1与28.7 µSv/MBq。
- 注射MVK配体的健康志愿者尿样中检出[68Ga]Ga-NOTA-Met-OH酶解片段,表明该策略在人体中起效。
- 患者PET/CT示HER2阳性病灶SUVmax范围9.4-21,HER2阴性病灶为2.7-6.2,提示MVK修饰未影响ZHER2:2891结构与HER2的结合能力。
关键数值与推荐
- [68Ga]Ga-NOTA-MVK-ZHER2:2891在PBS和小鼠血清中均稳定。
- 健康志愿者注射后1小时肾脏SUVmean:MVK配体34.3 vs 对照配体45.8(P<0.05)。
- 有效剂量:MVK配体26.1 µSv/MBq vs 对照配体28.7 µSv/MBq。
- 患者病灶SUVmax范围:HER2阳性9.4-21 vs HER2阴性2.7-6.2。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Enzymolysis clearance strategy, characterized by releasing the non-reabsorbable radioactive fragment under the specific cleavage of enzymes, is confirmed to be a safe and effective way to reduce the renal radioactivity accumulation in mice. However, the effectiveness of this strategy in humans remains unknown. Human epidermal growth factor receptor 2 (HER2) is overexpressed in various types of tumors, and radiolabeled HER2 Affibody is believed to be an attractive tool for HER2-targeted theranostics. However, its wide application is limited by the high and persistent renal uptake. In this study, we intend to validate the effectiveness of enzymolysis clearance strategy in reducing renal accumulation by using a modified HER2 Affibody. MATERIALS AND METHODS: A new HER2 Affibody ligand, NOTA-MVK-ZHER2:2891, containing a cleavable Met-Val-Lys (MVK) linker was synthesized and labeled with 68Ga. The microPET imaging study was performed in SKOV-3 tumor mice to assess the uptakes of the control ligand and the MVK one in tumors and kidneys. Seven healthy volunteers were included for biodistribution and dosimetric studies with both the control and MVK ligands performed 1 week apart. Urine and blood samples from healthy volunteers were collected for in vivo metabolism study of the two ligands. Four HER2-positive and two HER2-negative patients were recruited for [68Ga]Ga-NOTA-MVK-ZHER2:2891 PET/CT imaging at 2 and 4 h post-injection (p.i.). RESULTS: [68Ga]Ga-NOTA-MVK-ZHER2:2891 was stable both in PBS and in mouse serum. MicroPET images showed that the tumor uptake of [68Ga]Ga-NOTA-MVK-ZHER2:2891 was comparable to that of [68Ga]Ga-NOTA-ZHER2:2891 at all the time points, while the kidney uptake was significantly reduced 40 min p.i. (P < 0.05). The biodistribution study in healthy volunteers showed that the kidney uptake of MVK ligand was significantly lower than that of the control ligand at 1 h p.i. (P < 0.05), with the SUVmean of 34.3 and 45.8, respectively, while the uptakes of the two ligands in the other organs showed negligible difference. The effective doses of the MVK ligand and the control one were 26.1 and 28.7 µSv/MBq, respectively. The enzymolysis fragment of [68Ga]Ga-NOTA-Met-OH was observed in the urine samples of healthy volunteers injected with the MVK ligand, indicating that the enzymolysis clearance strategy worked in humans. The PET/CT study of patients showed that the range of SUVmax of HER2-positive lesions was 9.4-21, while that of HER2-negative lesions was 2.7-6.2, which suggested that the MVK modification did not affect the ability of ZHER2:2891 structure to bind with HER2. CONCLUSION: We for the first time demonstrated that enzymolysis clearance strategy can effectively reduce renal radioactivity accumulation in humans. This strategy is expected to decrease renal radiation dose of peptide and small protein-based radiotracers, especially in the field of radionuclide therapy.
引用
- Zhang M, Kang F, Xing T, et al. First-in-human validation of enzymolysis clearance strategy for decreasing renal radioactivity using modified [68Ga]Ga-HER2 Affibody. Eur J Nucl Med Mol Imaging. 2024. PMID: 38216779. doi:10.1007/s00259-023-06584-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。